Start Date
January 31, 2006
Primary Completion Date
December 31, 2007
Study Completion Date
December 31, 2007
atypical antipsychotic drug
For SSRI-refractory group, either atypical antipsychotic such as mean doses of RIS (3.1±1.9mg/day), of OLZ (5.1±3.2mg/day), and of QET (60.0±37.3mg/day) was added on ongoing SSRI(Paroxetine, Fluvoxamine).
exposure response prevention
After at least 12 weeks from treatment initiation, cognitive-behavioral therapy (CBT) using exposure and response prevention was added with psychoeducational interventions and behavioral analysis.
Dept of Neuropsychiatry, Osaka City University, graduate School of Medicine, Osaka
Osaka City University
OTHER